Phase 3 N=7 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
HTLV I Associated Myelopathy
Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 2 N=29 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
Phase 2 N=15 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
Adult T-cell Leukemia-Lymphoma · ATLL
Primary: Number of Participants Achieving Complete Molecular Response in Blood Compartment (CMR) — 3 Participants
Phase 2 N=23 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Adult T-Cell Lymphoma (ATL)
Primary: Objective Response Rate — 7 Participants
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 2 N=27 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Adult T-cell Leukemia-lymphoma
Primary: Overall Response Rate (ORR) — 50 percentage of participants with response
Phase 1 N=11 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
T-Cell Lymphoma Relapsed · Adult T-Cell Leukemia (ATL) · Peripheral T-Cell Lymphoma (PTCL)
Primary: Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) — 2 mcg/kg/dose
Phase 2 N=34 Anti-Tac for Treatment of Leukemia
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Phase 1 N=16 Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Adult T-Cell Leukemia and Lymphoma (ATL) · Adult Peripheral T-Cell Lymphoma (PTCL)
Primary: Incidence of Dose-Limiting Toxicities (DLTs) — 1 participants
Phase 1 N=12 TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Phase 2 N=26 A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Adult T-Cell Leukemia-Lymphoma
Primary: Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee…
Phase 2 N=38 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Phase 1 N=6 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Adult T-Cell Lymphoma/Leukemia · Sezary Syndrome · Mycosis Fungoides
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15) — 2 mcg/kg/day
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
N/A N=5 Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
Hereditary Transthyretin Amyloidosis (ATTRv) · Polyneuropathy
Primary: Change in Neuropathy Impairment Score (NIS) at Month 12 for ATTRv — 1.6 Change in score*months
Phase 2 N=71 KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Adult T-cell Leukemia-Lymphoma
Primary: Overall Response Rate — 2; 0; 0; 0 participants
Phase 1 N=118 HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Percent Change in HERV-K Level — -30.7 Percent change
N/A N=15 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
Hereditary Spastic Paraplegia · Adrenomyeloneuropathy
Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 2 N=9 Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Transplantation, Homologous · Transplantation, Autologous · Multiple Myeloma
Primary: Incidence of Graft Versus Host Disease (GvHD) — 1 Participants
Phase 2 N=43 Autologous Transplant in HIV Patients (BMT CTN 0803)
Lymphoma · HIV
Primary: Overall Survival (OS) — 87.3; 82 percentage of participants
Phase 2 N=20 Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease…
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=27 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
HIV Infections
Primary: Anti-Tat Antibody Titer — 698; 4 ng/mL
Phase 2 N=22 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myeloproliferative Disorder
Primary: Full-dose Donor Chimerism (FDC) at Day 28 Following TLI/ATG/TBI Conditioning. — 13 Participants